There is a need for validation of task performances against AD biomarkers like abnormal amyloid beta–positron emission tomography (Aβ-PET), or abnormal Aβ in cerebrospinal fluid (CSF), or abnormal tau-PET, or abnormal tau in CSF—before considering using these approaches on their own. This evidence concerns the gene MAPT and Alzheimer disease.